AVNRT

1. Executive Overview: What is AVNRT?

Atrioventricular Nodal Reentrant Tachycardia (AVNRT) is the most common type of paroxysmal supraventricular tachycardia (PSVT). Classified under ICD-10 code I47.1, it is a cardiac arrhythmia characterized by a rapid, regular heartbeat that originates above the ventricles. Specifically, it involves the atrioventricular (AV) node, the "gatekeeper" of the heart’s electrical conduction system.

In a healthy heart, electrical impulses travel in an orderly fashion from the sinus node to the AV node and then to the ventricles. In patients with AVNRT, a "short circuit" develops within or near the AV node, causing the electrical signal to loop continuously. This creates a feedback loop that forces the heart to beat at an abnormally high rate—typically between 120 and 220 beats per minute. While AVNRT is rarely life-threatening in structurally normal hearts, the sudden onset and rapid heart rate can significantly impair quality of life and necessitate clinical intervention.

2. Pathophysiology, Etiology, and Risk Factors

The Mechanism of Reentry

The fundamental pathophysiology of AVNRT is dual AV nodal physiology. In a normal heart, the AV node conducts electrical impulses at a single speed. In individuals predisposed to AVNRT, the AV node possesses two distinct pathways:

• The "Slow" Pathway: Conducts electrical impulses slowly but has a short refractory period.
• The "Fast" Pathway: Conducts electrical impulses rapidly but has a longer refractory period.

When a premature atrial contraction (PAC) occurs at a specific time, it may be blocked by the "fast" pathway (which is still in its refractory period) but travel down the "slow" pathway. By the time the signal reaches the bottom of the node, the "fast" pathway has recovered. The signal then travels backward (retrograde) up the "fast" pathway, creating a continuous loop.

Etiology and Risk Factors

AVNRT is not typically caused by underlying structural heart disease, though it can coexist with it. It is often idiopathic. Known risk factors and triggers include:

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of AVNRT is usually abrupt in onset and cessation, often described by patients as a "sudden switch" being flipped.

Common Symptoms

• Palpitations: A sensation of a racing or pounding heart.
• Dizziness or Lightheadedness: Due to transient decreases in cardiac output.
• Dyspnea: Shortness of breath during episodes.
• Chest Tightness: Often caused by the rapid heart rate rather than coronary ischemia.
• Syncope: Fainting occurs in a minority of patients, usually due to sudden vasodilation or extreme tachycardia.
• Neck Pounding: The "frog sign"—a sensation of pulsation in the neck caused by the atria contracting against a closed tricuspid valve.

4. Standard Diagnostic Evaluation & Workup

The diagnostic gold standard for AVNRT is the 12-lead Electrocardiogram (ECG) during an episode, or an Electrophysiology Study (EPS) for definitive mapping.

Diagnostic Modalities

1. 12-Lead ECG: During an episode, the ECG typically shows a narrow-complex tachycardia. A hallmark sign is the presence of "pseudo-R waves" in lead V1 or "pseudo-S waves" in the inferior leads (II, III, aVF), which represent the retrograde P-wave buried in the QRS complex.
2. Holter/Event Monitoring: Used for patients with frequent but transient episodes to capture the rhythm during a symptomatic event.
3. Electrophysiology Study (EPS): An invasive procedure where catheters are threaded into the heart to map the electrical pathways. This is the definitive diagnostic tool if non-invasive methods are inconclusive.
4. Laboratory Assays: Essential to rule out secondary causes. These include:
   • Thyroid Function Tests (TSH): To rule out hyperthyroidism.
   • Serum Electrolytes: Specifically potassium, magnesium, and calcium.
   • Complete Blood Count (CBC): To rule out anemia.

5. Therapeutic Interventions

Management is stratified by the clinical stability of the patient.

Acute Management (Terminating the Episode)

• Vagal Maneuvers: Carotid sinus massage or the Valsalva maneuver (bearing down) can increase vagal tone and terminate the circuit.
• Pharmacotherapy: If maneuvers fail, Adenosine is the first-line intravenous medication. It causes a brief AV nodal block, effectively "resetting" the heart’s electrical system.
• Electrical Cardioversion: Reserved for hemodynamically unstable patients (hypotension, altered mental status).

Long-Term Management

• Catheter Ablation: The gold standard for curative treatment. Using radiofrequency energy or cryotherapy, the cardiologist destroys the "slow" pathway. This has a success rate exceeding 95% with a very low risk of complications.
• Pharmacologic Prophylaxis: For patients who decline or are not candidates for ablation, rate-control medications such as Beta-blockers (e.g., Metoprolol) or Calcium Channel Blockers (e.g., Verapamil, Diltiazem) are prescribed to prevent recurrence.
• Lifestyle Modification: Reducing intake of caffeine, alcohol, and nicotine, and maintaining adequate hydration.

6. Frequently Asked Questions (FAQ)

1. Is AVNRT a form of heart disease?
AVNRT is an electrical conduction disorder, not a structural disease. Most patients have structurally normal hearts.

2. Can AVNRT be cured?
Yes, catheter ablation is considered a curative procedure for the vast majority of patients.

3. Is AVNRT life-threatening?
In patients without underlying heart disease, AVNRT is generally not life-threatening, though it can cause significant discomfort.

4. What does a "pseudo-R wave" mean on my ECG?
It is a specific ECG finding where the retrograde P-wave is hidden within the QRS complex, creating the appearance of an extra wave, which is diagnostic for AVNRT.

5. Why do I feel a "thump" in my neck?
This is known as the "frog sign." It happens because the atria are contracting while the tricuspid valve is closed, causing a backflow of pressure into the jugular veins.

6. Can caffeine trigger an episode?
Yes, stimulants like caffeine, nicotine, and certain over-the-counter decongestants can increase sympathetic tone and serve as triggers for an episode.

7. How long does the ablation procedure take?
The procedure typically takes 1 to 2 hours, and most patients are discharged the same day or the following morning.

8. Do I need to be on blood thinners for AVNRT?
Usually, no. Unlike Atrial Fibrillation, AVNRT does not typically carry a high risk of blood clots, so anticoagulation is rarely indicated unless other risk factors exist.

9. Can I exercise with AVNRT?
Yes, provided the condition is well-managed. However, if you experience symptoms during exercise, you should consult your cardiologist before proceeding with high-intensity training.

10. What is the success rate of catheter ablation?
The success rate for AVNRT ablation is extremely high, generally reported between 95% and 98%, with a very low risk of needing a permanent pacemaker.

Disclaimer: This guide is for educational purposes and does not substitute professional medical advice, diagnosis, or treatment. Always seek the advice of your cardiologist or a qualified healthcare provider with any questions regarding a medical condition.

Related Clinical Integration

In the modern clinical management of AVNRT, a structured approach is essential for both acute stabilization and definitive long-term therapy. During an acute symptomatic episode, rapid termination of the re-entrant tachycardia is typically achieved through the administration of Adenosine / أدينوسين 6mg/2ml, while patients requiring chronic rhythm control may be transitioned to maintenance therapy with Verapamil ER / فيراباميل ممتد المفعول (ER) 240mg. For patients presenting with recurrent or refractory symptoms, an Electrophysiology Study (EPS) / دراسة الفيزيولوجيا الكهربائية (EPS) (فحص بالمنظار أو أخذ عينات) is indicated to map the dual AV nodal pathways and facilitate curative catheter ablation. This interventional procedure relies on specialized equipment, such as the Diagnostic Catheter - Amplatz Left / قسطرة تشخيصية - أمبلاتز اليسرى, to ensure precise anatomical positioning and successful modification of the slow pathway.